# Liquid Biopsy as a Tool to Evaluate Resistance to First and Third (AZD9291) (EGFR) (TKIs) in (EGFR) Mutant NSCLC

> **NCT02771314** · PHASE2 · UNKNOWN · sponsor: **Hellenic Oncology Research Group** · enrollment: 48 (actual)

## Conditions studied

- Non Small Cell Lung Cancer

## Interventions

- **DRUG:** AZD9291

## Key facts

- **NCT ID:** NCT02771314
- **Lead sponsor:** Hellenic Oncology Research Group
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2016-08-02
- **Primary completion:** 2020-06
- **Final completion:** 2020-12
- **Target enrollment:** 48 (ACTUAL)
- **Last updated:** 2019-02-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02771314

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02771314, "Liquid Biopsy as a Tool to Evaluate Resistance to First and Third (AZD9291) (EGFR) (TKIs) in (EGFR) Mutant NSCLC". Retrieved via AI Analytics 2026-07-15 from https://api.ai-analytics.org/clinical/NCT02771314. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*